Compounded Tadalafil and Sildenafil: When the "Copy" Rule Applies

What the copy rule says, in four lines

As of October 2026, FDA's January 2018 guidance, restated in an April 1, 2026 FDA statement on GLP-1 pharmacies, says FDA considers a compounded drug essentially a copy of a commercially available drug when it has the same active ingredient, in the same, similar or easily substitutable strength, and the commercially available drug can be used by the same route (FDA guidance; FDA statement, April 1, 2026). The exception is a prescriber's determination that a change produces a significant difference for an identified individual patient, documented on the prescription. Four details matter to a telehealth operator:

• The statement has to be on the prescription. FDA says no particular format is needed if the prescription makes clear that the prescriber identified the change and the difference it produces for the patient. A prescription with only a patient name and formulation is not sufficient.
• Price does not count. FDA says other factors, such as a lower price, are not sufficient.
• Templates are a risk factor. FDA lists pre-printed prescription pads that skip the per-patient determination, and routine substitution, among the factors it may use to conclude a copy is compounded "regularly or in inordinate amounts."
• There is an enforcement threshold, not a safe harbor. FDA does not intend to act against a pharmacy that fills four or fewer prescriptions a month for an essentially-copy product, and prescriptions documenting a significant difference do not count toward the four.

The guidance is nonbinding and describes FDA's enforcement intentions. This article reports it for sourcing purposes; it is not legal advice and says nothing about clinical use.

Why this becomes a pharmacy-selection problem

Both medications have FDA-approved oral products, so whether a given compounded version holds up depends on the formulation and on what the prescriber documented, which differs by product and by patient. Two sourcing risks follow for a brand running hundreds or thousands of scripts a month:

• Pharmacy handling of gaps differs. A pharmacy that finds no statement on a prescription may contact the prescriber for a dated notation, as FDA's guidance describes, or decline the order.
• Your own order flow can undercut the documentation. A default template with no per-patient determination is the pattern FDA's list warns about.

A single pharmacy puts the whole ED line on one interpretation; direct contracts spread it across several portals.

Sourcing options compared for copy-rule exposure

The fourth row is the honest limit of any marketplace: the documented determination belongs to your prescribers, and it applies at every pharmacy. Failover covers stock and rejections; it is not a way around the documentation.

How AffinityRx solves compounded ED sourcing

1. Vetting before listing. Compliance (state licensures, USP <795>/<797>/<800>, LegitScript, PCAB, ACHC, NABP), product (third-party COAs, sterility and endotoxin testing, BUDs), track record (Form 483s, recalls, FDA actions, pharmacist-in-charge background), market feedback and operations. See the compliance vetting page.
2. Options side by side. Compare the same medication across pharmacies, with prices shown before ordering and turnaround shown per pharmacy. The price is set at signing.
3. Failover. Pre-set a primary pharmacy plus second and third favorites. If the primary is out of stock or rejects, the order moves automatically to the next favorite.
4. Alerts. If a pharmacy receives an FDA warning letter or recall, AffinityRx notifies clinics and updates the profile; you can switch that pharmacy off in your portal.
5. One integration. A headless API integration is about 1 day of dev work, with a test order the same day and sub-10-minute support replies. See the men's health telehealth page.
6. Pricing. $0 to join, no subscription, no per-order fees and no minimum order. Clinics typically save about 10% versus their current price (typical, not guaranteed).

Printable worksheet: copy-rule checklist for your ED line

Print this worksheet and complete it with your own records.

• Product, strength and route, and the nearest approved product: ________
• Prescriber's stated change and patient-specific difference, on the prescription: [ ]
• Order form requires the statement per patient, with no pre-filled default: [ ]
• Price or convenience is not the stated reason: [ ]
• Pharmacy process for missing statements (prescriber callback, dated notation): ________
• Records kept for at least three years, as FDA recommends: [ ]

FAQs

Book a demo

If your ED line depends on one pharmacy's reading of the copy rule, press the Book a demo button on the right side of this page and ask to see the compounded tadalafil and sildenafil options and the pharmacy vetting profiles.

Sources

• FDA: Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A (guidance, January 2018)
• FDA: statement on pharmacies, April 1, 2026